Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)

Summary

To determine the overall response rate to liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) administered by aerosolization in patients with non-small-cell lung cancer (any stage. To determine toxicity profile of L9NC administered by aerosolization for 5 consecutive days per week X 8 weeks, every 10 weeks. To perform a pharmacology study of L9NC in the plasma, and the lungs after aerosolization. A specific protocol will be written for this part.

Timeline

Start

2003-04

Primary completion

2007-12

Completion

2007-12

Drugs

Indications